Based on an analysis of withdrawn drugs that gained approval through the FDA's fast-track program, Columbia researchers argue that such programs have positively contributed to drug development.
Lisa Kachnic, MD, the new chair of radiation oncology at Columbia University Irving Medical Center, has helped pioneer techniques that deliver radiation therapy to cancer patients with more precision.
A new drug that penetrates the protective barrier around pancreatic cancers and accumulates in malignant cells may improve current chemotherapy, a study in mice suggests.
Researchers in Columbia's medical and engineering schools have edited a strain of non-pathogenic bacteria to colonize solid tumors in mice and safely deliver potent immunotherapies.
At Columbia, patients with brain cancer will be able to participate in a new type of clinical trial that promises to speed up the development of better drugs for glioblastoma.
Anil Rustgi, the new director of the Herbert Irving Comprehensive Cancer Center, talks about new ideas in cancer research, the best patient care, and the importance of physician-scientists.
Fewer than 1 in 10 patients with glioblastoma—the most common type of brain cancer—respond to immunotherapy; a new study reveals how to detect patients who may respond.
A multicenter study from SWOG Cancer Research Network found that infections with hepatitis B and C are common in new cancer patients, but few of these patients are screened for the viruses.